Zhongzhi Pharmaceutical Holdings (HKG:3737) plans to unwind its contractual arrangements with Zhongshan Zhongzhi Chinese Medicine Herb in Pieces as it can now directly hold equity interest in the latter, a Friday Hong Kong bourse filing said.
Zhongzhi Chinese Medicine Herb in Pieces is mainly engaged in the production of traditional and modern decoction pieces in China and is a major Chinese operating subsidiary of the group.
The company was not allowed to hold a direct interest in Zhongzhi Chinese Medicine Herb in Pieces due to the restrictions placed by the Foreign Investment Catalogue and had hence entered into contractual agreements to take management of and economic benefits from it.
As the said restrictions are now lifted in the Catalogue of Restricted Foreign Investment Industries (2024 version) issued by the National Development and Reform Commission on Sept. 8, the company now intends to hold equity interest in the Zhongzhi Chinese Medicine Herb in Pieces.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。